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Abstract Screening of blood films for the presence of
periodic acid-Schiff (PAS)-positive lymphocyte vacuoles is
sometimes used to support the diagnosis of Pompe disease,
but the actual diagnostic value is still unknown. We collected
peripheral blood films from 65 untreated Pompe patients and
51 controls. Lymphocyte vacuolization was quantified using
three methods: percentage vacuolated lymphocytes, percent-
age PAS-positive lymphocytes, and a PAS score depending
on staining intensity. Diagnostic accuracy of the tests was
assessed using receiver operating characteristic (ROC)
curves. All three methods fully discerned classic infantile
patients from controls. The mean values of patients with
milder forms of Pompe disease were significantly higher
than those of controls, but full separation was not obtained.
The area under the ROC curve was 0.98 for the percentage
vacuolated lymphocytes (optimal cutoff value 3; sensitivity
91%, specificity 96%) and 0.99 for the percentage PAS-
positive lymphocytes and PAS score (optimal cutoff value 9;
sensitivity 100%, specificity 98%). Our data indicate that
PAS-stained blood films can be used as a reliable screening
tool to support a diagnosis of Pompe disease. The percentage
of PAS-positive lymphocytes is convenient for use in clinical
practice but should always be interpreted in combination
with other clinical and laboratory parameters.
Abbreviations
ALAT Alanine aminotransferase
ASAT Aspartate aminotransferase
CK Creatine kinase
LAMP2 Lysosomal-associated membrane protein 2
MGG May-Grünwald/Giemsa
PAS Periodic acid-Schiff
ROC Receiver-operating characteristic
Introduction
Pompe disease (glycogen storage disease type II, acid
maltase deficiency; OMIM # 232300) is an inherited
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DOI 10.1007/s10545-009-9027-4metabolic disorder in which a deficiency of the lysosomal
enzyme acid α-glucosidase (EC 3.2.1.3/20) causes glyco-
gen storage. This leads to a continuum of phenotypes with
the rapidly progressive classic infantile form, which is
characterized by cardiomyopathy and generalized hypoto-
nia at the most severe end. Milder forms of the disease may
present at any age, with limb-girdle weakness as the most
prominent clinical feature (Hirschhorn and Reuser 2000;
van der Ploeg and Reuser 2008). The diagnosis of Pompe
disease is confirmed by measuring acid α-glucosidase
activity in leukocytes using the latest optimized procedures,
or in cultured fibroblasts (Hirschhorn and Reuser 2000; van
Diggelen et al. 2009; Winchester et al. 2008). These tests,
however, are carried out in a specialized laboratory and are
usually not applied unless there is already a strong
suspicion for Pompe disease. A reliable and simple test to
include or exclude Pompe disease in the differential
diagnosis would be of help to the clinician.
Glycogen storage in Pompe disease is found in lyso-
somes throughout the body, including lymphocytes in
peripheral blood (de Barsy and Hers 1975; Ikeda et al.
1982; Trend et al. 1985). Peripheral blood is easy to obtain,
and the presence of glycogen-filled vacuoles in lympho-
cytes can be detected by microscopic inspection of blood
films. As early as 1977, the potential usefulness of this test
on the path to diagnosing Pompe disease was discussed
(von Bassewitz et al. 1977). In current clinical practice, it is
sometimes used as a quick screening method before final
confirmation by enzymatic or genetic analysis (Muntoni et
al. 2005; Straub 2008a) or as a secondary test to support a
diagnosis of Pompe disease (Winchester et al. 2008), but
the test was never formally validated.
Vacuolated lymphocytes—in essence, lysosomes filled
with nondegraded material—occur in many storage disor-
ders. In a retrospective review of 2,550 blood films of
patients with a history suggestive of metabolic disease
(Anderson et al. 2005), vacuolated lymphocytes were
identified in 156 cases. Twenty-three percent of those were
from patients with Pompe disease: 15% for the rapidly
progressive classic infantile form and 8% for milder forms
presenting in childhood, adolescence, or adulthood. Other
diagnoses included juvenile Batten’s disease (31%), GM1
gangliosidosis (9%), galactosialidosis (5%), mucopolysac-
charidosis (5%), and I-cell disease (4%). Pompe disease
was the only disease in which lymphocytes were reported
to stain positively with periodic acid-Schiff (PAS) reagent
(Anderson et al. 2005). Based on the literature, the presence
of PAS-positive lymphocyte vacuoles seems to be specific
for Pompe disease (Anderson et al. 2005; de Barsy & Hers
1975; Ikeda et al. 1982; Straub 2008a; Trend et al. 1985),
but it was also noted that vacuolated lymphocytes are less
frequent in milder forms of the disease compared with the
classic infantile form (Anderson et al. 2005). In fact, the
actual diagnostic value of the test remains unknown unless
the frequency in Pompe disease is compared with a control
group.
We have collected peripheral blood films since 1999 as
part of the clinical and laboratory evaluation of patients
with Pompe disease. To investigate the diagnostic value
of the test for both classic infantile and milder forms, we
quantified the percentage of vacuolated lymphocytes, the
percentage of PAS-positive lymphocytes, and the inten-
s i t yo fP A Ss t a i n i n gi nag r o u po f6 5p a t i e n t sa n d5 1
controls.
Methods
Patients
Between January 1999 and December 2006, blood films
were obtained from 65 untreated patients: 8 babies with
classic infantile Pompe disease and 16 children and 41
adults with milder forms. Patients participated in studies
investigating the natural course of Pompe disease or the
effects of enzyme replacement therapy. All studies were
approved by the Medical Ethical Committee of Erasmus
MC, the Netherlands, and written informed consent was
obtained from patients and/or parents. In all patients, the
diagnosis of Pompe disease was confirmed by deficiency of
acid α-glucosidase activity in cultured fibroblasts or
leukocytes (Hirschhorn and Reuser 2000; Okumiya et al.
2006). From all patients, one or more blood films were
obtained before the start of enzyme replacement therapy
and from 16 patients during treatment.
Controls
Control values were obtained from 17 children visiting the
outpatient clinic of the departments of Metabolic Diseases
and Genetics, Endocrinology, or Gastro-enterology (Erasmus
MC-Sophia Children’s Hospital) and from whom a blood
sample was needed for routine clinical care. Exclusion criteria
were suspected or confirmed diagnosis of a lysosomal or
glycogen storage disorder, acute infection, or other diseases
that might affect the lymphocytes. Adult control values were
obtained from 34healthy blood donors (Sanquin Blood Bank,
Rotterdam, the Netherlands). The Medical Ethical Committee
of Erasmus MC approved the protocol to obtain control
samples. Informed consent was obtained from children and
their parents, as well as from all blood donors.
Lymphocyte scores
One blood sample was taken from every patient, and six
blood films were prepared. Two were stained with May-
134 J Inherit Metab Dis (2010) 33:133–139Grünwald/ Giemsa (MGG) reagent, two with PAS reagent,
and two were extras. All blood films were made within 2 h
of the sample being drawn. Staining and microscopic
inspection of the blood films was done within 1–5 days.
To quantify the degree of lymphocyte vacuolization, three
methods were used. First, the number of vacuolated
lymphocytes per 100 lymphocytes (percentage vacuolated
lymphocytes) was counted in the MGG-stained blood films.
For the second and third methods, PAS reagent was used to
stain for the presence of glycogen. The number of PAS-
positive lymphocytes per 100 lymphocytes was then
counted (percentage PAS-positive lymphocytes). Finally,
the presence of glycogen-filled vacuoles was quantified by
a PAS intensity score. This scoring method was originally
developed to quantify lymphocytic proliferation in leuke-
mia (Bain 1995; Hayhoe and Quaglino 1980; Mitus et al.
1958). Each lymphocyte received a score varying from 1 (a
small PAS-positive spot) to 4 (a large group of large PAS-
positive spots). Lymphocytes without PAS-positive
vacuoles were scored 0. The sum of the scores of 100
lymphocytes (PAS score) was then calculated. All scoring
was performed in duplicate (two different blood films by
two different observers), and the average of the two scores
was used in the analyses. Figure 1 shows photomicrographs
of blood films from patients with Pompe disease and a
healthy control.
Statistical analysis
Patients were subdivided in three groups: patients with
the severe classic infantile form of Pompe disease,
children under 18 years of age with delayed onset of
symptoms, and patients of 18 years and older. Likewise,
controls were divided in three subgroups: up to age 1,
between 1 and 18 years, and 18 years and older. Age,
sex, percentage of vacuolated lymphocytes, percentage
PAS-positive lymphocytes, and PAS score of patients
and controls were summarized using median, ranges,
and percentages. Differences between patient and con-
trol groups were compared with Pearson’s χ
2 test (ratio
men/women) and the Mann–Whitney test (age). Differ-
ences between groups in percentage of vacuolated lym-
phocytes, percentage PAS-positive lymphocytes, and PAS
s c o r ew e r et e s t e dw i t ht h eM a n n –Whitney test. When
more than one blood film per patient was available, the
most recent measurement before starting enzyme therapy
was used in the analyses.
To quantify the diagnostic accuracy of the test, receiver-
operating characteristic (ROC) curves were made for the
percentage of vacuolated lymphocytes, percentage PAS-
positive lymphocytes, and total PAS score. ROC curves
plot the true-positive rate (sensitivity) against the false-
positive rate (1- specificity) for all possible cutoff values.
Fig. 1 Photomicrographs of
blood films from patients with
Pompe disease and a healthy
control. a May-Grünwald/
Giemsa-stained blood film of a
late-onset Pompe patient show-
ing a lymphocyte with two
distinct vacuoles; b periodic
acid-Schiff (PAS)-stained blood
film of a healthy control (PAS
score = 0); c PAS-stained blood
film of a late-onset Pompe pa-
tient showing a lymphocyte with
PAS-positive inclusions (PAS
score = 2); d PAS-stained blood
film of a patient with classic
infantile Pompe disease showing
a lymphocyte with a larger
number of PAS-positive inclu-
sions (PAS score = 3)
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compared between the three tests.
The intraclass correlation coefficient was used to assess
agreement between repeated measurements within patients
from whom two or more samples were available before
start of enzyme therapy. The relation between test scores
and age was evaluated with Spearman correlation coef-
ficients. Differences in test scores between male and female
patients were tested with Mann–Whitney tests. All analyses
were performed using SPSS for Windows (version 15.0,
SPSS Inc. Chicago, IL, USA). A p value<0.05 was
considered significant.
Results
General characteristics
Table 1 shows the general characteristics of the patient and
control groups. The ratio between the number of infants,
children, and adults was 1:2:5 in the patient group and 1:3:8
in the control group. When the groups were compared, no
significant differences were found in age and male/female
ratio.
Test scores
Table 2 shows the percentage of vacuolated lymphocytes,
percentage of PAS-positive lymphocytes, and PAS scores
per subgroup of patients and controls. In Fig. 2, these
scores are plotted for classic infantile patients, children
and adults with Pompe disease, and controls. The figure
shows that all three methods fully discriminate between
classic infantile patients and controls. Values of older
children and adults with Pompe disease differed sig-
nificantly from those of controls (p<0.001 for all three
methods), but full separation was not obtained. Classic
infantile patients scored significantly higher (all p<0.001)
than children and adults with milder forms of the
disease.
Diagnostic accuracy
Diagnostic accuracy of the three tests was assessed using
ROC curves. With all patients and controls taken together,
the area under the ROC curve was 0.98 for the percentage
of vacuolated lymphocytes, and 0.99 for the percentage of
PAS-positive lymphocytes and PAS-score (Fig. 3). Because
classic infantile patients showed no overlap with controls,
we also calculated ROC curves only for children and adults
with milder forms of the disease and controls >1 year.
Results were comparable: the area under the curve was 0.97
for the percentage of vacuolated lymphocytes and 0.99 for
the percentage of PAS-positive lymphocytes and the PAS
score. ROC curves were then used to determine the optimal
cutoff value to discern between patients and controls.
Again, results for the total group were comparable with
those excluding classic infantile patients and controls
<1 year. Optimal cutoff values (upper left corner of the
curves) were determined as 3 for the percentage of
vacuolated lymphocytes (i.e., a score≥3 indicates a patient;
sensitivity 91%, specificity 96%) and 9 for the percentage
Table 1 General characteristics of patients with Pompe disease and controls
Number of patients Age [median (range)] Male/female (%)
Pompe patients
Classic infantile 8 4 (0–10) months 50/50
Milder form, <18 years 16 12 (3–17) years 69/31
Milder form, ≥18 years 41 49 (24–72) years 51/49
Total 65 38 (0–72) years 55/45
Controls
≤1 year
a 49 ( 0 –12) months 75/25
1–18 years
b 13 10 (3–15) years 62/38
≥18 years
c 34 58 (20–68) years 53/47
Total 51 43 (0–68) years 57/43
a Reasons for visiting the outpatient clinic of the Department of Metabolic Diseases and Genetics: biotinidase deficiency (n=2), phenylketonuria
(n=1), suspected galactosemia (n=1)
b Reasons for visiting the outpatient clinic of the Department of Metabolic Diseases and Genetics: hypercholesterolemia (n=1), lipoprotein lipase
deficiency (n=1), ornithine transcarbamylase deficiency (n=2), phenylketonuria (n=2), tyrosinemia (n=2); Department of Endocrinology:
adrenogenital syndrome (n=2), growth hormone deficiency (n=1), growth retardation (n=1); Gastroenterology: unknown reason (n=1).
c Healthy controls donating blood on a regular basis
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specificity 98%).
Within-patient variability
The study population included 26 patients with two or more
subsequent measurements before the start of enzyme
replacement therapy. Measurements, with intervals varying
between 5 days and 17.7 months (median 5.8 months),
showed moderate agreement: the intraclass correlation
coefficient was 0.69 for the percentage of vacuolated
lymphocytes, 0.62 for the percentage of PAS-positive
lymphocytes, and 0.68 for PAS-score.
Relationship with age and sex
No correlations between the percentage of vacuolated
lymphocytes, percentage of PAS-positive lymphocytes,
PAS-score, and age were found in subgroups with milder
forms of Pompe disease. For classic infantile patients, the
percentage of PAS-positive lymphocytes increased with age
(rs=0.71, p=0.049). A small but statistically significant
correlation with age was also present in the control group
(rs=0.33, 0.35 and 0.34; all p<0.02). No significant
differences in test scores between male and female patients
were found in any of the subgroups or the control group.
Effect of enzyme replacement therapy on PAS score
For 16 of the 65 patients, blood films from shortly
(maximum 3 weeks) before and after the start of treatment
were available. In all patients, the percentage of vacuolated
lymphocytes, percentage of PAS-positive lymphocytes, and
PAS score decreased greatly within a few weeks after the
start of enzyme replacement therapy to values in or
approximating the control range.
Discussion
We investigated whether quantification of glycogen-filled
vacuoles in peripheral blood lymphocytes would be of use
as a simple screening method to include or exclude Pompe
disease in the differential diagnosis. To this end, peripheral
blood films were collected from 65 patients with Pompe
disease and 51 controls. Using routine staining procedures
for light microscopy, the percentage of vacuolated lympho-
cytes was calculated. By staining the glycogen with PAS
reagent, two additional values were obtained: the percent-
age of PAS-positive lymphocytes and a PAS score
quantifying staining intensity. All three methods were able
to discern classic infantile Pompe patients from controls
without Pompe disease. Median scores of children and
adults with milder forms of the disease were also clearly
higher than those of the control group, but some overlap
still existed. Nevertheless, diagnostic accuracy of the tests
was very good, with areas under the ROC curve approach-
ing 100% for all three methods. Although all three methods
showed excellent results, the percentage of PAS-positive
lymphocytes and PAS score performed slightly better than
the percentage of vacuolated lymphocytes. Moreover, the
PAS reagent used for the first two measures specifically
stains glycogen accumulation, which is a hallmark of
Pompe disease. As the diagnostic accuracy was comparably
high for both the percentage of PAS-positive lymphocytes
and PAS score, it can be concluded that stain-intensity
quantification by adding a score to the PAS-stained
lymphocytes is not necessary.
With a cutoff value of 9 for the percentage of PAS-
positive lymphocytes, a sensitivity of 100% and a specific-
ity of 98% were reached. The 100% sensitivity means that
no patients should be missed; a specificity of 98% means
that the test is likely to give a false positive result in 2% of
cases. The latter will be detected when further diagnostic
Table 2 Vacuolated lymphocytes, periodic acid-Schiff (PAS)-positive lymphocytes, and PAS scores of patients with Pompe disease and controls
Number Percent vacuolated lymphocytes
[median (range)]
Percent PAS-positive lymphocytes
[median (range)]
PAS score
[median (range)]
Pompe patients
Classic infantile 8 56 (25–79) 82 (40–96) 123 (77–163)
Milder form, <18 years 16 10 (0–40) 37 (10–67) 40 (10–87)
Milder form, ≥18 years 41 9 (1–52) 37 (16–58) 40 (16–68)
Total 65 10 (0–79) 39 (10–96) 45 (10–163)
Controls
≤1 year 4 0 (0–0) 2 (1–3) 2 (1–3)
1–18 years 13 0 (0–1) 2 (0–7) 2 (0–8)
≥18 years 34 1 (0–3) 3 (0–15) 3 (0–19)
Total 51 0 (0–3) 2 (0–15) 2 (0–19)
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turns out to be within the normal range. It should be noted,
however, that we found considerable within-patient vari-
ability in subsequent measurements. Some variability
between observers and laboratories is likely to exist as
well. In clinical practice, a low percentage of PAS-positive
lymphocyte vacuoles should therefore not automatically
exclude the possibility of Pompe disease, especially when
the patient is an adolescent or adult. The test result should
always be considered in combination with other results—
for example, creatine kinase (CK), alanine aminotransferase
(ALAT), and aspartate aminotransferase (ASAT) (Winkel et
al. 2005)—and a careful clinical examination. On the other
hand, when a high percentage of PAS-positive lymphocyte
vacuoles is found, further testing by measuring acid α-
glucosidase activity in leukocytes (van Diggelen et al.
2009) is always indicated. This fits into previously
proposed diagnostic algorithms for childhood- and adult-
onset Pompe disease (Straub 2008b).
Another issue that should be addressed is our choice of
the control group—which consisted of children without
Pompe disease, lysosomal disease, or glycogen storage
Fig. 2 Dot plots of a percentage of vacuolated lymphocytes, b
percentage periodic acid-Schiff (PAS)-positive lymphocytes, and c
PAS scores of 65 patients with Pompe disease and 51 controls. 0
controls (n=51); 1 classic infantile patients (n=8); 2 children with
Pompe disease (n=16); 3 adults with Pompe disease (n=41)
Fig. 3 Receiver operating characteristic (ROC) curves for the
percentage of vacuolated lymphocytes, percentage of periodic acid-
Schiff (PAS)-positive lymphocytes, and PAS-score of 65 patients with
Pompe disease and 51 controls. ——— percentage of vacuolated
lymphocytes; •— —•— —• percentage of PAS positive lymphocytes;
—— —— PAS score; •—•—• reference line
138 J Inherit Metab Dis (2010) 33:133–139disease and healthy adult controls. It could be argued that in
most cases of suspected Pompe disease, one would rather
want to discern patients with Pompe disease from patients
with other diseases causing generalized weakness and
hypertrophic cardiomyopathy (infants) or limb-girdle weak-
ness (children, adolescents, and adults). To our knowledge
PAS-positive vacuolar pathology in peripheral lymphocytes
is not described for such disorders, although it could
perhaps be expected in Danon disease (LAMP2 cardiomy-
opathy) (Maron et al. 2009). As for other metabolic
diseases, PAS-positive staining of lymphocytes, although
not yet reported, might be present in oligosaccharidosis or
nonlysosomal glycogen storage diseases. However, these
disorders either differ in clinical symptoms, or PAS staining
is not expected to be restricted to vacuoles.
Ofnote,thenumberofglycogen-filledlymphocytevacuoles
decreased rapidly after the start of treatment with recombinant
human α-glucosidase. Nevertheless, it is not likely to be a
suitable marker for treatment efficacy, as there is no apparent
link to clinical effects on heart, muscle, and liver (Winkel et al.
2003). In conclusion, we have shown that quantification of
PAS-positive lymphocytes in peripheral blood films performs
well in discerning patients with Pompe disease from controls.
The test can be used as a reliable and simple screening
method to support a diagnosis of Pompe disease.
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